KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma

BACKGROUND: In the KEYNOTE-022 study, pembrolizumab with dabrafenib and trametinib (triplet) improved progression-free survival (PFS) versus placebo with dabrafenib and trametinib (doublet) without reaching statistical significance. Mature results on PFS, duration of response (DOR), and overall surv...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferrucci, Pier Francesco, Di Giacomo, Anna Maria, Del Vecchio, Michele, Atkinson, Victoria, Schmidt, Henrik, Schachter, Jacob, Queirolo, Paola, Long, Georgina V, Stephens, Rosalie, Svane, Inge Marie, Lotem, Michal, Abu-Amna, Mahmoud, Gasal, Eduard, Ghori, Razi, Diede, Scott J, Croydon, Elizabeth S, Ribas, Antoni, Ascierto, Paolo Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7768966/
https://www.ncbi.nlm.nih.gov/pubmed/33361337
http://dx.doi.org/10.1136/jitc-2020-001806

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7768966/
https://www.ncbi.nlm.nih.gov/pubmed/33361337
http://dx.doi.org/10.1136/jitc-2020-001806

Ejemplares similares